{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:27:15Z","timestamp":1794414435151,"version":"4.9.1"},"reference-count":558,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pharmthera.2026.109126","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:58:01Z","timestamp":1789570681000},"page":"109126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Drug resistance in cancer: Emerging mechanisms, translational barriers, and pharmacological strategies"],"prefix":"10.1016","volume":"288","author":[{"given":"Xiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinguo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Qi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunxiang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Charles R.","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0005","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1038\/s41467-024-53017-7","article-title":"Cancer treatment monitoring using cell-free DNA fragmentomes","volume":"15","author":"van \u2019t Erve","year":"2024","journal-title":"Nature Communications"},{"issue":"7655","key":"10.1016\/j.pharmthera.2026.109126_bb0010","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0015","doi-asserted-by":"crossref","first-page":"22654","DOI":"10.1038\/s41598-023-50007-5","article-title":"Circulating ESR1, long non-coding RNA HOTAIR and microRNA-130a gene expression as biomarkers for breast cancer stage and metastasis","volume":"13","author":"Abdel-Hamid","year":"2023","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0020","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12967-022-03405-8","article-title":"Patient-derived xenograft (PDX) models, applications and challenges in cancer research","volume":"20","author":"Abdolahi","year":"2022","journal-title":"Journal of Translational Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051139","article-title":"The practicality of the use of liquid biopsy in early diagnosis and treatment monitoring of Oral cancer in resource-limited settings","volume":"14","author":"Adeola","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"26","key":"10.1016\/j.pharmthera.2026.109126_bb0030","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2174\/138161211797440186","article-title":"Breast cancer resistance protein and P-glycoprotein in brain cancer: Two gatekeepers team up","volume":"17","author":"Agarwal","year":"2011","journal-title":"Current Pharmaceutical Design"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb0035","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/s41591-020-1060-8","article-title":"Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: A randomized phase 2 trial","volume":"26","author":"Algazi","year":"2020","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060471","article-title":"Increase of O-glycosylated oncofetal fibronectin in high glucose-induced epithelial-mesenchymal transition of cultured human epithelial cells","volume":"8","author":"Alisson-Silva","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunological Reviews"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109126_bb0050","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Al-Lazikani","year":"2012","journal-title":"Nature Biotechnology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb0055","first-page":"417","article-title":"Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C","volume":"1","author":"Allen","year":"2002","journal-title":"Molecular Cancer Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0060","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: Updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Molecular Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0065","doi-asserted-by":"crossref","first-page":"9332","DOI":"10.1038\/s41598-019-45863-z","article-title":"Interplay of Darwinian selection, Lamarckian induction and microvesicle transfer on drug resistance in cancer","volume":"9","author":"\u00c1lvarez-Arenas","year":"2019","journal-title":"Scientific Reports"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb0070","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/2159-8290.CD-19-0292","article-title":"Targeting autophagy in cancer: Recent advances and future directions","volume":"9","author":"Amaravadi","year":"2019","journal-title":"Cancer Discovery"},{"issue":"47","key":"10.1016\/j.pharmthera.2026.109126_bb0075","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: From genomics to mechanism","volume":"22","author":"Ambudkar","year":"2003","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0080","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13046-023-02725-x","article-title":"The lncRNA HOTAIR: A pleiotropic regulator of epithelial cell plasticity","volume":"42","author":"Amicone","year":"2023","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109126_bb0085","first-page":"6101","article-title":"An informatics approach identifying markers of chemosensitivity in human cancer cell lines","volume":"60","author":"Amundson","year":"2000","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109126_bb0090","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"5381","key":"10.1016\/j.pharmthera.2026.109126_bb0095","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1126\/science.281.5381.1305","article-title":"Death receptors: Signaling and modulation","volume":"281","author":"Ashkenazi","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10555-007-9049-z","article-title":"Molecular basis of antifolate resistance","volume":"26","author":"Assaraf","year":"2007","journal-title":"Cancer Metastasis Reviews"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb0105","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s12276-024-01180-8","article-title":"Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer","volume":"56","author":"Bae","year":"2024","journal-title":"Experimental & Molecular Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb0110","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood.V100.4.1224.h81602001224_1224_1232","article-title":"Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and leukemia group B study 9720","volume":"100","author":"Baer","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pharmthera.2014.05.007","article-title":"Small-molecule SMAC mimetics as new cancer therapeutics","volume":"144","author":"Bai","year":"2014","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1718256","article-title":"Nanocarrier-based delivery of siRNA therapeutics in rheumatoid arthritis: Immune mechanisms and translational perspectives","volume":"16","author":"Bai","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"54","key":"10.1016\/j.pharmthera.2026.109126_bb0125","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.1038\/sj.onc.1208955","article-title":"Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs","volume":"24","author":"Baker","year":"2005","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb0130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Research"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109126_bb0135","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1038\/s41591-025-03735-2","article-title":"Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics","volume":"31","author":"Bao","year":"2025","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0140","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.drup.2017.05.002","article-title":"Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance","volume":"31","author":"Bar-Zeev","year":"2017","journal-title":"Drug Resistance Updates"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109126_bb0150","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.18632\/oncotarget.1875","article-title":"Epigenetic plasticity: A central regulator of epithelial-to-mesenchymal transition in cancer","volume":"5","author":"Bedi","year":"2014","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109126_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112362","article-title":"ABC transporters in cancer stem cells: Beyond chemoresistance","volume":"18","author":"Begicevic","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109126_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143466","article-title":"Extracellular matrices and cancer-associated fibroblasts: Targets for cancer diagnosis and therapy?","volume":"13","author":"Belhabib","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb0165","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41416-019-0648-6","article-title":"Principles and mechanisms of non-genetic resistance in cancer","volume":"122","author":"Bell","year":"2020","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2015.49","article-title":"Lipid metabolic reprogramming in cancer cells","volume":"5","author":"Beloribi-Djefaflia","year":"2016","journal-title":"Oncogenesis"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb0175","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41416-019-0717-x","article-title":"Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration","volume":"122","author":"Beloueche-Babari","year":"2020","journal-title":"British Journal of Cancer"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb0180","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109126_bb0185","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1158\/1078-0432.CCR-04-0795","article-title":"Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias","volume":"10","author":"Benderra","year":"2004","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1490898","article-title":"Bisphenol a and DDT disrupt adipocyte function in the mammary gland: Implications for breast cancer risk and progression","volume":"15","author":"Bernhardt","year":"2025","journal-title":"Frontiers in Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb0195","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"issue":"7283","key":"10.1016\/j.pharmthera.2026.109126_bb0200","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0205","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jsbmb.2014.02.002","article-title":"Bisphenol-a and diethylstilbestrol exposure induces the expression of breast cancer associated long noncoding RNA HOTAIR in vitro and in vivo","volume":"141","author":"Bhan","year":"2014","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0210","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10555-024-10172-z","article-title":"Cancer cell plasticity: From cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance","volume":"43","author":"Bhat","year":"2024","journal-title":"Cancer Metastasis Reviews"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109126_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246091","article-title":"Combination of STING and TLR 7\/8 agonists as vaccine adjuvants for cancer immunotherapy","volume":"14","author":"Bhatnagar","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0220","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12964-025-02185-0","article-title":"A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemia","volume":"23","author":"Bica","year":"2025","journal-title":"Cell Communication and Signaling: CCS"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb0225","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line Camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"The New England Journal of Medicine"},{"issue":"6320","key":"10.1016\/j.pharmthera.2026.109126_bb0230","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(00)74210-3","article-title":"Treatment of staphylococcal infections with penicillin by intermittent sterilisation","volume":"244","author":"Bigger","year":"1944","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0235","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.isci.2018.05.011","article-title":"Ras post-transcriptionally enhances a pre-malignantly primed EMT to promote invasion","volume":"4","author":"Bisogno","year":"2018","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb0240","first-page":"153","article-title":"PDX models for functional precision oncology and discovery science","volume":"25","author":"Blanchard","year":"2025","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0245","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","article-title":"Pathways of antigen processing","volume":"31","author":"Blum","year":"2013","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neulet.2014.09.015","article-title":"IDH1 regulates phospholipid metabolism in developing astrocytes","volume":"582","author":"Bogdanovic","year":"2014","journal-title":"Neuroscience Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0255","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-020-01007-9","article-title":"MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents","volume":"13","author":"Bolomsky","year":"2020","journal-title":"Journal of Hematology & Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb0260","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41419-024-06674-x","article-title":"ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC","volume":"15","author":"B\u00f6pple","year":"2024","journal-title":"Cell Death & Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: Tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb0270","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional addiction in Cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0275","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13046-022-02297-2","article-title":"Epigenetic remodelling in human hepatocellular carcinoma","volume":"41","author":"Braghini","year":"2022","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb0280","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1158\/1078-0432.CCR-05-1966","article-title":"Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: Effect on tumor-infiltrating T cells","volume":"12","author":"Brandacher","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb0285","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.trsl.2013.11.003","article-title":"Extracellular matrix as an inductive scaffold for functional tissue reconstruction","volume":"163","author":"Brown","year":"2014","journal-title":"Translational Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb0290","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41568-025-00795-x","article-title":"Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection","volume":"25","author":"Bruhm","year":"2025","journal-title":"Nature Reviews Cancer"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb0295","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.molonc.2014.06.005","article-title":"Tumour heterogeneity and the evolution of polyclonal drug resistance","volume":"8","author":"Burrell","year":"2014","journal-title":"Molecular Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb0300","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nature Reviews Cancer"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109126_bb0305","article-title":"The Spt10 GNAT superfamily protein modulates development, cell cycle progression and virulence in the fungal insect pathogen, Beauveria bassiana","volume":"7","author":"Cai","year":"2021","journal-title":"Journal of Fungi (Basel)"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb0310","article-title":"Application of cancer organoids: The forefront of personalized oncology and preclinical testing","volume":"1","author":"Cao","year":"2025","journal-title":"OR"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0315","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cancergen.2025.12.001","article-title":"Genetic modulation of ABCB1: Sunvozertinib reverses ABCB1-mediated multidrug resistance in cancer cells","volume":"300-301","author":"Cao","year":"2026","journal-title":"Cancer Genetics"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb0320","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrc3483","article-title":"Cancer metabolism: Fatty acid oxidation in the limelight","volume":"13","author":"Carracedo","year":"2013","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0325","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7053451","article-title":"Long-term alteration of reactive oxygen species led to multidrug resistance in MCF-7 cells","volume":"2016","author":"Cen","year":"2016","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8090320","article-title":"Investigating core signaling pathways of hepatitis B virus pathogenesis for biomarkers identification and drug discovery via systems biology and deep learning method","volume":"8","author":"Chang","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0335","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-0716-0759-6_10","article-title":"Extracellular vesicles and their roles in cancer progression","volume":"2174","author":"Chang","year":"2021","journal-title":"Methods in Molecular Biology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0340","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101062","article-title":"The role of ABCC10\/MRP7 in anti-cancer drug resistance and beyond","volume":"73","author":"Chen","year":"2024","journal-title":"Drug Resistance Updates"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0350","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12957-025-04135-z","article-title":"Advances in the use of exosomes for the diagnosis and treatment of ovarian cancer","volume":"24","author":"Chen","year":"2025","journal-title":"World Journal of Surgical Oncology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0355","article-title":"The role of PD-1 signaling in health and immune-related diseases","volume":"14","author":"Chen","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb0360","article-title":"GSH as an A-A type allosteric activator of PKM2: Modulating cancer cell homeostasis and Ferroptosis susceptibility","volume":"13","author":"Chen","year":"2026","journal-title":"Advanced Science (Weinh)"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0365","article-title":"Predictive value of KDM5C alterations for immune checkpoint inhibitors treatment outcomes in patients with cancer","volume":"12","author":"Chen","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb0370","doi-asserted-by":"crossref","DOI":"10.1002\/mog2.70015","article-title":"Characteristic, regulation and targeting strategies of cancer stem cells and their niche in digestive system tumors","volume":"4","author":"Chen","year":"2025","journal-title":"MedComm \u2013 Oncology"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109126_bb0375","first-page":"4048","article-title":"Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: Effects of acquired mutations at R482 on methotrexate transport","volume":"63","author":"Chen","year":"2003","journal-title":"Cancer Research"},{"issue":"Pt B","key":"10.1016\/j.pharmthera.2026.109126_bb0380","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.ijbiomac.2017.10.154","article-title":"Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K\/Akt and Wnt\/\u03b2-catenin signaling pathways by up-regulating miR-34a","volume":"107","author":"Cheng","year":"2018","journal-title":"International Journal of Biological Macromolecules"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0385","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-025-01722-1","article-title":"Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance","volume":"18","author":"Cheng","year":"2025","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0390","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12916-022-02614-8","article-title":"Combination of an autophagy inhibitor with immunoadjuvants and an anti-PD-L1 antibody in multifunctional nanoparticles for enhanced breast cancer immunotherapy","volume":"20","author":"Cheng","year":"2022","journal-title":"BMC Medicine"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102274","article-title":"Targeting FABP4\/UCP2 axis to overcome cetuximab resistance in obesity-driven CRC with drug-tolerant persister cells","volume":"53","author":"Cheng","year":"2025","journal-title":"Translational Oncology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109126_bb0400","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115862","article-title":"Tumor extracellular matrix stiffness promptly modulates the phenotype and gene expression of infiltrating T lymphocytes","volume":"22","author":"Chiriv\u00ec","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0405","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1475-2867-5-30","article-title":"ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal","volume":"5","author":"Choi","year":"2005","journal-title":"Cancer Cell International"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118309","article-title":"Super-enhancer PPP1R15B\/EIF2A axis characterizes aggressive drug-tolerant persister cells in glioblastoma","volume":"189","author":"Chuang","year":"2025","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0415","first-page":"1","article-title":"Role of in vitro two-dimensional (2D) and three-dimensional (3D) cell culture systems for ADME-Tox screening in drug discovery and development: A comprehensive review","volume":"11","author":"Chunduri","year":"2023","journal-title":"Admet dmpk"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109126_bb0420","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115812","article-title":"The Hyaluronan\/CD44 Axis: A double-edged sword in cancer","volume":"24","author":"Cirillo","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0425","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev.biochem.77.062706.153223","article-title":"The biology of chromatin remodeling complexes","volume":"78","author":"Clapier","year":"2009","journal-title":"Annual Review of Biochemistry"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb0430","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evidence"},{"issue":"45","key":"10.1016\/j.pharmthera.2026.109126_bb0435","doi-asserted-by":"crossref","first-page":"30880","DOI":"10.1074\/jbc.R114.609248","article-title":"Multidrug resistance protein 1 (MRP1, ABCC1), a \"multitasking\" ATP-binding cassette (ABC) transporter","volume":"289","author":"Cole","year":"2014","journal-title":"Journal of Biological Chemistry"},{"issue":"7519","key":"10.1016\/j.pharmthera.2026.109126_bb0440","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100319","article-title":"Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer","volume":"6","author":"Coleman","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0450","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fonc.2018.00327","article-title":"The network of non-coding RNAs in cancer drug resistance","volume":"8","author":"Corr\u00e0","year":"2018","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0455","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1476-4598-6-61","article-title":"Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines","volume":"6","author":"Cosse","year":"2007","journal-title":"Molecular Cancer"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109126_bb0460","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076046","article-title":"ABCB1 and ABCC1 function during TGF-\u03b2-induced epithelial-mesenchymal transition: Relationship between multidrug resistance and tumor progression","volume":"24","author":"da Costa","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb0465","doi-asserted-by":"crossref","DOI":"10.3390\/jcm15062311","article-title":"Overcoming chemotherapy resistance in triple-negative breast cancer with nanocarrier-delivered siRNA therapeutics","volume":"15","author":"Crintea","year":"2026","journal-title":"Journal of Clinical Medicine"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109126_bb0470","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood-2010-04-277269","article-title":"Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: A randomized, placebo-controlled trial of the eastern cooperative oncology group 3999","volume":"116","author":"Cripe","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0475","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41698-022-00337-w","article-title":"The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells","volume":"6","author":"Criscione","year":"2022","journal-title":"npj Precision Oncology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb0480","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0485","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.17179\/excli2025-8617","article-title":"IFN-gamma in the tumor microenvironment: Dual roles in cancer progression and therapy","volume":"24","author":"Cui","year":"2025","journal-title":"EXCLI Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100105","article-title":"Targeting fatty acid synthase for cancer drug discovery: Retrospective analyses and outlook","volume":"78","author":"Cui","year":"2026","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0495","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.freeradbiomed.2022.03.003","article-title":"Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways","volume":"183","author":"Cui","year":"2022","journal-title":"Free Radical Biology & Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0500","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0505","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12974-022-02400-6","article-title":"Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1\/Nrf2\/HO-1\/Gpx4 pathway","volume":"19","author":"Dang","year":"2022","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0510","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2017.08.020","article-title":"Manumycin a suppresses exosome biogenesis and secretion via targeted inhibition of Ras\/Raf\/ERK1\/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells","volume":"408","author":"Datta","year":"2017","journal-title":"Cancer Letters"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb0515","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cellular & Molecular Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb0520","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: Translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0525","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241264704","article-title":"Adaptive Cancer therapy in the age of generative artificial intelligence","volume":"31","author":"Derbal","year":"2024","journal-title":"Cancer Control"},{"issue":"6958","key":"10.1016\/j.pharmthera.2026.109126_bb0530","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-beta family signalling","volume":"425","author":"Derynck","year":"2003","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109126_bb0535","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1158\/0008-5472.CAN-21-3844","article-title":"Drug-tolerant Persister cells in cancer therapy resistance","volume":"82","author":"Dhanyamraju","year":"2022","journal-title":"Cancer Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109126_bb0540","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb0545","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41419-021-03854-x","article-title":"Role of noncoding RNA in drug resistance of prostate cancer","volume":"12","author":"Ding","year":"2021","journal-title":"Cell Death & Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0550","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40164-025-00648-1","article-title":"RNA modifications in the tumor microenvironment: Insights into the cancer-immunity cycle and beyond","volume":"14","author":"Ding","year":"2025","journal-title":"Experimental Hematology & Oncology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb0555","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1172\/JCI69741","article-title":"Targeting lactate metabolism for cancer therapeutics","volume":"123","author":"Doherty","year":"2013","journal-title":"The Journal of Clinical Investigation"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109126_bb0560","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/s41419-020-03189-z","article-title":"Exosomes and breast cancer drug resistance","volume":"11","author":"Dong","year":"2020","journal-title":"Cell Death & Disease"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109126_bb0565","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: A novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Annals of Oncology"},{"issue":"26","key":"10.1016\/j.pharmthera.2026.109126_bb0570","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb0575","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1078-0432.CCR-15-2013","article-title":"A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer","volume":"22","author":"Drilon","year":"2016","journal-title":"Clinical Cancer Research"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109126_bb0580","doi-asserted-by":"crossref","first-page":"5810","DOI":"10.1158\/0008-5472.CAN-16-0716","article-title":"Chromatin-remodeling complex SWI\/SNF controls multidrug resistance by transcriptionally regulating the drug efflux pump ABCB1","volume":"76","author":"Dubey","year":"2016","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb0585","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.trecan.2023.09.013","article-title":"Linking ABC transporters to the hallmarks of cancer","volume":"10","author":"Duvivier","year":"2024","journal-title":"Trends Cancer"},{"issue":"7182","key":"10.1016\/j.pharmthera.2026.109126_bb0590","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb0595","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12892","article-title":"The mir-465 family is upregulated with age and attenuates growth hormone signaling in mouse liver","volume":"18","author":"Elias","year":"2019","journal-title":"Aging Cell"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0600","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.891652","article-title":"Multidrug resistance in cancer: Understanding molecular mechanisms, immunoprevention and therapeutic approaches","volume":"12","author":"Emran","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"5827","key":"10.1016\/j.pharmthera.2026.109126_bb0605","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb0610","first-page":"328","article-title":"Immune checkpoint inhibitor resistance in soft tissue sarcoma","volume":"5","author":"Eulo","year":"2022","journal-title":"Cancer Drug Resistance"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb0615","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12030251","article-title":"Potential intersections between lncRNA, vascular cognitive impairment, and immunization strategies: Insights and future directions","volume":"12","author":"Fan","year":"2024","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb0620","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/ncb3312","article-title":"Organoids as an in vitro model of human development and disease","volume":"18","author":"Fatehullah","year":"2016","journal-title":"Nature Cell Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0625","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12935-022-02599-7","article-title":"Cancer-associated fibroblasts and resistance to anticancer therapies: Status, mechanisms, and countermeasures","volume":"22","author":"Feng","year":"2022","journal-title":"Cancer Cell International"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0630","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13046-023-02615-2","article-title":"The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma","volume":"42","author":"Feng","year":"2023","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175853","article-title":"Isoorientin reverses lung cancer drug resistance by promoting ferroptosis via the SIRT6\/Nrf2\/GPX4 signaling pathway","volume":"954","author":"Feng","year":"2023","journal-title":"European Journal of Pharmacology"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109126_bb0640","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911023","article-title":"Anticancer therapeutic strategies targeting p53 aggregation","volume":"23","author":"Ferretti","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb0645","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer Metastasis Reviews"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0650","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-cancerbio-050216-121919","article-title":"Stress-induced mutagenesis: Implications in cancer and drug resistance","volume":"1","author":"Fitzgerald","year":"2017","journal-title":"Annual Review of Cancer Biology"},{"issue":"6348","key":"10.1016\/j.pharmthera.2026.109126_bb0655","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189455","article-title":"Animal models in preclinical evaluation of CAR-T cell therapy: Advantages and limitations","volume":"1880","author":"Fl\u00f8e","year":"2025","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0665","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0670","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev-pathmechdis-051222-122423","article-title":"Update on epithelial-mesenchymal plasticity in cancer progression","volume":"19","author":"Fontana","year":"2024","journal-title":"Annual Review of Pathology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb0675","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00280-015-2845-1","article-title":"Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors","volume":"76","author":"Fox","year":"2015","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0680","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.3389\/fmicb.2017.02483","article-title":"The importance of ncRNAs as epigenetic mechanisms in phenotypic variation and organic evolution","volume":"8","author":"Fr\u00edas-Lasserre","year":"2017","journal-title":"Frontiers in Microbiology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109126_bb0685","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","article-title":"ERCC1 isoform expression and DNA repair in non-small-cell lung cancer","volume":"368","author":"Friboulet","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0690","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1038\/s41467-019-12321-3","article-title":"CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity","volume":"10","author":"Fu","year":"2019","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0695","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41698-024-00757-w","article-title":"Targeting ErbB and tankyrase1\/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer","volume":"8","author":"Fujimura","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb0700","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ijc.24064","article-title":"Tumor resistance to apoptosis","volume":"124","author":"Fulda","year":"2009","journal-title":"International Journal of Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb0705","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrd3627","article-title":"Targeting IAP proteins for therapeutic intervention in cancer","volume":"11","author":"Fulda","year":"2012","journal-title":"Nature Reviews Drug Discovery"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb0710","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discovery"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb0715","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1365-2141.2002.03538.x","article-title":"In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia","volume":"117","author":"Galmarini","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb0720","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202451102","article-title":"Metabolic dialogue shapes immune response in the tumor microenvironment","volume":"55","author":"Gao","year":"2025","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0725","doi-asserted-by":"crossref","first-page":"14853","DOI":"10.2147\/IJN.S566173","article-title":"Advancing epigenetic combination therapy in oncology: Multifunctional nano-drug delivery systems for synergistic efficacy and precision modulation","volume":"20","author":"Gao","year":"2025","journal-title":"International Journal of Nanomedicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109126_bb0730","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-020-0411-1","article-title":"Integrating evolutionary dynamics into cancer therapy","volume":"17","author":"Gatenby","year":"2020","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109126_bb0740","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive therapy","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Research"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109126_bb0745","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41585-023-00726-1","article-title":"Preclinical models of prostate cancer \u2014 Modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo","volume":"20","author":"Germain","year":"2023","journal-title":"Nature Reviews Urology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109126_bb0750","article-title":"Lipid metabolism and resistance to anticancer treatment","volume":"9","author":"Germain","year":"2020","journal-title":"Biology-Basel"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0755","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3762\/bjnano.12.31","article-title":"The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR\/CD44-positive solid tumors","volume":"12","author":"Geskovski","year":"2021","journal-title":"Beilstein Journal of Nanotechnology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0760","first-page":"964","article-title":"Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma","volume":"7","author":"Ghannam","year":"2026","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0765","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s41065-025-00564-8","article-title":"Cancer cell plasticity and therapeutic resistance: Mechanisms, crosstalk, and translational perspectives","volume":"162","author":"Ghorbian","year":"2025","journal-title":"Hereditas"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb0770","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nature Reviews Drug Discovery"},{"issue":"5531","key":"10.1016\/j.pharmthera.2026.109126_bb0775","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0780","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: Role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nature Reviews Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb0785","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jhep.2015.11.011","article-title":"Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche","volume":"64","author":"Govaere","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"7381","key":"10.1016\/j.pharmthera.2026.109126_bb0790","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0795","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djt347","article-title":"Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial","volume":"106","author":"Greenhalf","year":"2014","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0800","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s43018-026-01114-5","article-title":"Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC","volume":"7","author":"Greenwald","year":"2026","journal-title":"Nature Cancer"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb0805","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ncb1722","article-title":"The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1","volume":"10","author":"Gregory","year":"2008","journal-title":"Nature Cell Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0810","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: Triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb0815","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22030365","article-title":"Effect of oxidative stress on ABC transporters: Contribution to epilepsy pharmacoresistance","volume":"22","author":"Grewal","year":"2017","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb0820","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.molonc.2014.05.004","article-title":"Drug resistance to targeted therapies: Deja vu all over again","volume":"8","author":"Groenendijk","year":"2014","journal-title":"Molecular Oncology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0825","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1757-2215-3-8","article-title":"The detection, treatment, and biology of epithelial ovarian cancer","volume":"3","author":"Gubbels","year":"2010","journal-title":"Journal of Ovarian Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109126_bb0830","doi-asserted-by":"crossref","DOI":"10.3390\/vetsci12111029","article-title":"MicroRNA expression profiling in canine Myxomatous mitral valve disease highlights potential diagnostic tool and molecular pathways","volume":"12","author":"Guelfi","year":"2025","journal-title":"Veterinary Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb0835","first-page":"4885","article-title":"The action mechanism of lncRNA-HOTAIR on the drug resistance of non-small cell lung cancer by regulating Wnt signaling pathway","volume":"15","author":"Guo","year":"2018","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0840","first-page":"119842","article-title":"Metabolic vulnerabilities in ovarian cancer decoding the nexus between nutrient adaptation and therapy resistance","volume":"203","author":"Guo","year":"2026","journal-title":"Journal of Advanced Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0845","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12964-026-02681-x","article-title":"Exosome RAB10 inhibits JAK1\/STAT1 to hinder macrophage M1 polarization and promote tumor immune escape","volume":"24","author":"Guohui","year":"2026","journal-title":"Cell Communication and Signaling: CCS"},{"issue":"7291","key":"10.1016\/j.pharmthera.2026.109126_bb0850","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08975","article-title":"Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis","volume":"464","author":"Gupta","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0855","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1258691","article-title":"Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer-associated fibroblasts in colon carcinoma","volume":"14","author":"Hajiabadi","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"7743","key":"10.1016\/j.pharmthera.2026.109126_bb0860","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-0916-x","article-title":"Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells","volume":"566","author":"Han","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0865","article-title":"The role of B2M in cancer immunotherapy resistance: Function, resistance mechanism, and reversal strategies","volume":"16","author":"Han","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb0870","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"7679","key":"10.1016\/j.pharmthera.2026.109126_bb0875","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109126_bb0880","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201798589","article-title":"Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt\u2019s lymphoma","volume":"37","author":"Hartleben","year":"2018","journal-title":"The EMBO Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb0885","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0890","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","article-title":"Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb0895","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109126_bb0900","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1042\/BCJ20170712","article-title":"The role of metabolism and tunneling nanotube-mediated intercellular mitochondria exchange in cancer drug resistance","volume":"475","author":"Hekmatshoar","year":"2018","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0905","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Design, Development and Therapy"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109126_bb0910","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s00018-009-0053-z","article-title":"Nanocarriers\u2019 entry into the cell: Relevance to drug delivery","volume":"66","author":"Hillaireau","year":"2009","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb0915","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","article-title":"HALO 202: Randomized phase II study of PEGPH20 plus nab-paclitaxel\/gemcitabine versus nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma","volume":"36","author":"Hingorani","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb0920","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-enhancers in the control of cell identity and disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109126_bb0925","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1158\/0008-5472.CAN-25-0351","article-title":"Adaptive therapy exploits fitness deficits in chemotherapy-resistant ovarian cancer to achieve long-term tumor control","volume":"85","author":"Hockings","year":"2025","journal-title":"Cancer Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb0930","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: An evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nature Reviews. Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb0935","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1124\/mol.106.022624","article-title":"Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin","volume":"70","author":"Holzer","year":"2006","journal-title":"Molecular Pharmacology"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109126_bb0940","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1158\/0008-5472.CAN-03-3111","article-title":"Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): Resistance to docetaxel","volume":"64","author":"Hopper-Borge","year":"2004","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb0945","doi-asserted-by":"crossref","DOI":"10.3390\/epigenomes5030016","article-title":"Can immune suppression and epigenome regulation in placenta offer novel insights into cancer immune evasion and immunotherapy resistance?","volume":"5","author":"Hossain","year":"2021","journal-title":"Epigenomes"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0950","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10238-025-01965-9","article-title":"AI-driven multi-omics integration in precision oncology: Bridging the data deluge to clinical decisions","volume":"26","author":"Hsu","year":"2025","journal-title":"Clinical and Experimental Medicine"},{"issue":"45","key":"10.1016\/j.pharmthera.2026.109126_bb0955","article-title":"SLC6A14 drives mitochondrial fusion and oxidative phosphorylation to promote cancer stemness and early-onset of breast cancer","volume":"12","author":"Hu","year":"2025","journal-title":"Advanced Science (Weinh)"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0960","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3389\/fonc.2020.00934","article-title":"TRPS1 confers multidrug resistance of breast cancer cells by regulating BCRP expression","volume":"10","author":"Hu","year":"2020","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0965","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13046-019-1120-4","article-title":"Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer","volume":"38","author":"Huang","year":"2019","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109126_bb0970","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bbrc.2023.09.021","article-title":"AXL receptor tyrosine kinase inhibition improves the anti-tumor effects of CD8(+) T cells by inducing CD103(+) dendritic cell-mediated T cell priming","volume":"680","author":"Im","year":"2023","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb0975","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2009.07.015","article-title":"Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma","volume":"115","author":"Inaba","year":"2009","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb0980","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/10409238.2017.1412395","article-title":"The impact of non-genetic heterogeneity on cancer cell death","volume":"53","author":"Inde","year":"2018","journal-title":"Critical Reviews in Biochemistry and Molecular Biology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109126_bb0985","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1158\/1078-0432.CCR-07-4144","article-title":"Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: Its association with disease progression and survival","volume":"14","author":"Ino","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb0990","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.humpath.2015.06.008","article-title":"Hypoxia-mediated cancer stem cells in pseudopalisades with activation of hypoxia-inducible factor-1\u03b1\/Akt axis in glioblastoma","volume":"46","author":"Inukai","year":"2015","journal-title":"Human Pathology"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109126_bb0995","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.1073\/pnas.162491399","article-title":"Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals","volume":"99","author":"Ishida","year":"2002","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1000","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fphar.2019.00203","article-title":"Metabolism-based therapeutic strategies targeting cancer stem cells","volume":"10","author":"Jagust","year":"2019","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb1005","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.molcel.2005.06.027","article-title":"The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription","volume":"19","author":"Jang","year":"2005","journal-title":"Molecular Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","article-title":"Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors","volume":"3","author":"Jaspers","year":"2013","journal-title":"Cancer Discovery"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb1015","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations\u2014A mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12967-025-06098-x","article-title":"Super-enhancers in tumors: Unraveling recent advances in their role in oncogenesis and the emergence of targeted therapies","volume":"23","author":"Ji","year":"2025","journal-title":"Journal of Translational Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1030","article-title":"Network-based prediction of anti-cancer drug combinations","volume":"15","author":"Jiang","year":"2024","journal-title":"Frontiers in Pharmacology"},{"issue":"31","key":"10.1016\/j.pharmthera.2026.109126_bb1035","article-title":"A super-enhancer-driven transcriptional regulatory circuit underlying Abiraterone resistance in castration-resistant prostate cancer","volume":"12","author":"Jiang","year":"2025","journal-title":"Advanced Science (Weinh)"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1447678","article-title":"Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer","volume":"14","author":"Jiang","year":"2024","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1050","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103458","article-title":"Inhibiting de novo lipogenesis identifies a therapeutic vulnerability in therapy-resistant colorectal cancer","volume":"79","author":"Jog","year":"2025","journal-title":"Redox Biology"},{"issue":"7326","key":"10.1016\/j.pharmthera.2026.109126_bb1055","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109126_bb1060","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nchembio.2087","article-title":"Structural analysis of human KDM5B guides histone demethylase inhibitor development","volume":"12","author":"Johansson","year":"2016","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1065","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40778-020-00182-2","article-title":"Integration of mechanical and ECM microenvironment signals in the determination of cancer stem cell states","volume":"7","author":"Jokela","year":"2021","journal-title":"Current Stem Cell Reports"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb1070","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.32604\/or.2025.067126","article-title":"Cancer 3D models: Essential tools for understanding and overcoming drug resistance","volume":"33","author":"Jovanovi\u0107 Stojanov","year":"2025","journal-title":"Oncology Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1075","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.694","article-title":"Single-cell RNA sequencing technologies and applications: A brief overview","volume":"12","author":"Jovic","year":"2022","journal-title":"Clinical and Translational Medicine"},{"issue":"6230","key":"10.1016\/j.pharmthera.2026.109126_bb1080","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1085","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochimica et Biophysica Acta"},{"issue":"7467","key":"10.1016\/j.pharmthera.2026.109126_bb1090","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb1095","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500447","article-title":"Mammalian SWI\/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics","volume":"1","author":"Kadoch","year":"2015","journal-title":"Science Advances"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1100","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxrep.2024.101884","article-title":"Metabolomics integrated genomics approach: Understanding multidrug resistance phenotype in MCF-7 breast cancer cells exposed to doxorubicin and ABCA1\/EGFR\/PI3k\/PTEN crosstalk","volume":"14","author":"Kadry","year":"2025","journal-title":"Toxicology Reports"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109126_bb1105","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.trecan.2023.07.006","article-title":"Beyond matrix stiffness: Targeting force-induced cancer drug resistance","volume":"9","author":"Kalli","year":"2023","journal-title":"Trends Cancer"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb1110","doi-asserted-by":"crossref","first-page":"8131","DOI":"10.1007\/s00432-023-04737-8","article-title":"Cancer immune escape: The role of antigen presentation machinery","volume":"149","author":"Kallingal","year":"2023","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1115","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"British Journal of Pharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb1120","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nature Reviews. Cancer"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109126_bb1125","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI200320530","article-title":"Epithelial-mesenchymal transition and its implications for fibrosis","volume":"112","author":"Kalluri","year":"2003","journal-title":"The Journal of Clinical Investigation"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb1130","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12964-025-02144-9","article-title":"Mechanical cues rewire lipid metabolism and support chemoresistance in epithelial ovarian cancer cell lines OVCAR3 and SKOV3","volume":"23","author":"Karasov\u00e1","year":"2025","journal-title":"Cell Communication and Signaling: CCS"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1140","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1158\/1078-0432.CCR-10-1725","article-title":"A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer","volume":"17","author":"Kelly","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-3-642-14541-4_8","article-title":"Multidrug resistance proteins (MRPs, ABCCs): Importance for pathophysiology and drug therapy","volume":"201","author":"Keppler","year":"2011","journal-title":"Handbook of Experimental Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1150","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-025-04141-x","article-title":"Multi-tyrosine kinase inhibitors: Exploring immunomodulatory effects on various immune cell types in cancer","volume":"26","author":"Keshavarz","year":"2026","journal-title":"Cancer Cell International"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1155","doi-asserted-by":"crossref","first-page":"15473","DOI":"10.1038\/s41598-021-94941-8","article-title":"Rapid signaling reactivation after targeted BRAF inhibition predicts the proliferation of individual melanoma cells from an isogenic population","volume":"11","author":"Khoshkenar","year":"2021","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb1160","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040861","article-title":"The emerging roles of exosomes as EMT regulators in cancer","volume":"9","author":"Kim","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109126_bb1165","doi-asserted-by":"crossref","DOI":"10.3390\/biom11081161","article-title":"Clinical perspectives of single-cell RNA sequencing","volume":"11","author":"Kim","year":"2021","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb1170","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1681\/ASN.2012010070","article-title":"Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection","volume":"23","author":"Kinsey","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1175","first-page":"147","article-title":"EGFR T790M: Revealing the secrets of a gatekeeper","volume":"8","author":"Ko","year":"2017","journal-title":"Lung Cancer (Auckl)"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109126_bb1180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218027","article-title":"Radiotherapy-resistant breast cancer cells enhance tumor progression by enhancing premetastatic niche formation through the HIF-1\u03b1-LOX Axis","volume":"21","author":"Ko","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109126_bb1185","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb1190","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ccell.2018.03.025","article-title":"A convergence-based framework for cancer drug resistance","volume":"33","author":"Konieczkowski","year":"2018","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb1195","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discovery"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109126_bb1200","first-page":"4147","article-title":"Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: Results of the MIRROS trial","volume":"6","author":"Konopleva","year":"2022","journal-title":"Blood Advances"},{"issue":"7626","key":"10.1016\/j.pharmthera.2026.109126_bb1205","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109126_bb1210","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1158\/1535-7163.MCT-08-0021","article-title":"Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin","volume":"7","author":"Kovalchuk","year":"2008","journal-title":"Molecular Cancer Therapeutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1215","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"35","key":"10.1016\/j.pharmthera.2026.109126_bb1220","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1039\/D2SC02708A","article-title":"In situ monitoring of functional activity of extracellular matrix stiffness-dependent multidrug resistance protein 1 using scanning electrochemical microscopy","volume":"13","author":"Kuermanbayi","year":"2022","journal-title":"Chemical Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1225","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Molecular Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb1230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020597","article-title":"Immunosurveillance and Immunoediting of lung cancer: Current perspectives and challenges","volume":"21","author":"Kunimasa","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1235","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"issue":"7511","key":"10.1016\/j.pharmthera.2026.109126_bb1240","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nature13393","article-title":"Targeting transcription regulation in cancer with a covalent CDK7 inhibitor","volume":"511","author":"Kwiatkowski","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1245","article-title":"Matrix metalloproteinases as therapeutic targets in breast cancer","volume":"12","author":"Kwon","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1652398","article-title":"Super-enhancers in immune system regulation: Mechanisms, pathological reprogramming, and therapeutic opportunities","volume":"16","author":"Lai","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb1255","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18050779","article-title":"Drug-tolerant Persister cells and tumor dormancy in NSCLC: A new frontier in overcoming therapeutic resistance","volume":"18","author":"Lalla","year":"2026","journal-title":"Cancers (Basel)"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2026.109126_bb1260","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000320172","article-title":"Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-\u03b2-induced epithelial-mesenchymal transition","volume":"193","author":"Lamouille","year":"2011","journal-title":"Cells, Tissues, Organs"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1573202","article-title":"Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: A case report","volume":"16","author":"Lang","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb1270","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/ncb3039","article-title":"PGC-1\u03b1 mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis","volume":"16","author":"LeBleu","year":"2014","journal-title":"Nature Cell Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1275","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40364-025-00757-3","article-title":"Extracellular matrix: Unlocking new avenues in cancer treatment","volume":"13","author":"Lee","year":"2025","journal-title":"Biomarker Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb1280","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.slasd.2023.03.006","article-title":"Three-dimensional (3D) cell culture tools for spheroid and organoid models","volume":"28","author":"Lee","year":"2023","journal-title":"SLAS Discovery"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1285","doi-asserted-by":"crossref","DOI":"10.4110\/in.2026.26.e9","article-title":"Dynamic interplay between tumor cells and the immune system","volume":"26","author":"Lee","year":"2026","journal-title":"Immune Network"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-026-00538-9","article-title":"Advanced drug delivery strategies for overcoming biological barriers: Tumor microenvironment and blood-brain barrier","volume":"26","author":"Lei","year":"2026","journal-title":"Drugs in R&D"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1295","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.265","article-title":"Understanding and targeting resistance mechanisms in cancer","volume":"4","author":"Lei","year":"2023","journal-title":"MedComm"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1300","first-page":"1086","article-title":"Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1\/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia","volume":"94","author":"Leith","year":"1999","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb1305","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1634\/theoncologist.8-5-411","article-title":"The role of ABC transporters in clinical practice","volume":"8","author":"Leonard","year":"2003","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb1310","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"British Journal of Cancer"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109126_bb1315","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/s41563-024-01908-x","article-title":"Engineered matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids","volume":"23","author":"LeSavage","year":"2024","journal-title":"Nature Materials"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb1320","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrc.2017.53","article-title":"Targeting autophagy in cancer","volume":"17","author":"Levy","year":"2017","journal-title":"Nature Reviews Cancer"},{"issue":"40","key":"10.1016\/j.pharmthera.2026.109126_bb1325","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1038\/s41388-022-02444-1","article-title":"GSTM2 is a key molecular determinant of resistance to SG-ARIs","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1330","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13046-021-01974-y","article-title":"Super-enhancers: A new frontier for epigenetic modifiers in cancer chemoresistance","volume":"40","author":"Li","year":"2021","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1335","article-title":"Drug-tolerant persister cell in cancer: Reversibility, microenvironmental interplay, and therapeutic strategies","volume":"16","author":"Li","year":"2025","journal-title":"Frontiers in Pharmacology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109126_bb1340","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00262-025-04221-x","article-title":"Research progress in the construction and application of immunotherapy resistance models","volume":"74","author":"Li","year":"2025","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109126_bb1345","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1158\/0008-5472.CAN-20-1420","article-title":"How tumor cell dedifferentiation drives immune evasion and resistance to immunotherapy","volume":"80","author":"Li","year":"2020","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1350","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70586","article-title":"Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance","volume":"16","author":"Li","year":"2026","journal-title":"Clinical and Translational Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109126_bb1355","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nchembio.1661","article-title":"Hydrolysis of 2\u20323\u2019-cGAMP by ENPP1 and design of nonhydrolyzable analogs","volume":"10","author":"Li","year":"2014","journal-title":"Nature Chemical Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1360","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s13287-024-04061-z","article-title":"Exosome crosstalk between cancer stem cells and tumor microenvironment: cancer progression and therapeutic strategies","volume":"15","author":"Li","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1365","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9133658","article-title":"The role of cancer stem cell-derived exosomes in cancer progression","volume":"2022","author":"Li","year":"2022","journal-title":"Stem Cells International"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1370","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12951-022-01382-0","article-title":"Extracellular vesicle-mediated crosstalk between pancreatic cancer and stromal cells in the tumor microenvironment","volume":"20","author":"Li","year":"2022","journal-title":"Journal of Nanobiotechnology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1375","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.1038\/s41467-022-34271-z","article-title":"De novo analysis of bulk RNA-seq data at spatially resolved single-cell resolution","volume":"13","author":"Liao","year":"2022","journal-title":"Nature Communications"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb1380","doi-asserted-by":"crossref","DOI":"10.1093\/pcmedi\/pbaf022","article-title":"A pan-cancer analysis revealed SKP2 as an inhibitor of the tumor immune microenvironment and a promising therapeutic target for immunotherapy","volume":"8","author":"Liao","year":"2025","journal-title":"Precision Clinical Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb1385","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","article-title":"Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance","volume":"20","author":"Liau","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1390","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jncc.2025.09.007","article-title":"Temporal dynamics in cancer immunotherapy: The interplay between circadian rhythms, tumor microenvironment, and immune checkpoint blockade","volume":"6","author":"Lin","year":"2026","journal-title":"Journal of the National Cancer Center"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109126_bb1395","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrd4626","article-title":"SLC transporters as therapeutic targets: Emerging opportunities","volume":"14","author":"Lin","year":"2015","journal-title":"Nature Reviews Drug Discovery"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1400","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ng.3218","article-title":"The hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies","volume":"47","author":"Lin","year":"2015","journal-title":"Nature Genetics"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1405","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102579","article-title":"Drug-tolerant persister cells in head and neck squamous cell carcinoma: Molecular mechanisms and therapeutic opportunities","volume":"63","author":"Ling","year":"2026","journal-title":"Translational Oncology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115547","article-title":"Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update","volume":"225","author":"Lipson","year":"2025","journal-title":"European Journal of Cancer"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb1415","article-title":"BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer","volume":"119","author":"Liu","year":"2022","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1420","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/21655979.2021.1880732","article-title":"T-box transcription factor TBX1, targeted by microRNA-6727-5p, inhibits cell growth and enhances cisplatin chemosensitivity of cervical cancer cells through AKT and MAPK pathways","volume":"12","author":"Liu","year":"2021","journal-title":"Bioengineered"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1425","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/biom14030253","article-title":"SynerGNet: A graph neural network model to predict anticancer drug synergy","volume":"14","author":"Liu","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2025.101043","article-title":"Cutting-edge drug resistance analysis of major cancers at single-cell level","volume":"45","author":"Liu","year":"2025","journal-title":"Cancer Treatment and Research Communications"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb1435","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10585-023-10246-2","article-title":"Dissecting the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics","volume":"41","author":"Liu","year":"2024","journal-title":"Clinical & Experimental Metastasis"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1440","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ccell.2018.02.005","article-title":"Tumor-repopulating cells induce PD-1 expression in CD8(+) T cells by transferring kynurenine and AhR activation","volume":"33","author":"Liu","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1445","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: Technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1450","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jare.2024.05.031","article-title":"Unlocking the crucial role of cancer-associated fibroblasts in tumor metastasis: Mechanisms and therapeutic prospects","volume":"71","author":"Liu","year":"2025","journal-title":"Journal of Advanced Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1455","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12943-025-02477-6","article-title":"Turning cold tumors into hot tumors to ignite immunotherapy","volume":"24","author":"Liu","year":"2025","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1460","unstructured":"Lockwood, C.M., et al., Circulating tumor DNA testing in solid tumors and lymphoma: ASCO guideline. JCO Oncology Practice 0(0): p. OP\u201326\u201300311."},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb1465","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1124\/mol.51.6.1034","article-title":"ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene","volume":"51","author":"Loe","year":"1997","journal-title":"Molecular Pharmacology"},{"issue":"9992","key":"10.1016\/j.pharmthera.2026.109126_bb1470","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109126_bb1475","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109126_bb1480","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.apsb.2025.05.009","article-title":"Artificial intelligence and anti-cancer drugs\u2019 response","volume":"15","author":"Long","year":"2025","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb1485","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","article-title":"Molecular mechanisms of drug resistance","volume":"205","author":"Longley","year":"2005","journal-title":"Journal of Pathology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1490","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","article-title":"Combine and conquer: Challenges for targeted therapy combinations in early phase trials","volume":"14","author":"Lopez","year":"2017","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"7381","key":"10.1016\/j.pharmthera.2026.109126_bb1495","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"issue":"6330","key":"10.1016\/j.pharmthera.2026.109126_bb1500","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb1505","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1158\/1078-0432.CCR-13-1610","article-title":"Molecular pathways: Resistance to kinase inhibitors and implications for therapeutic strategies","volume":"20","author":"Lovly","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1510","doi-asserted-by":"crossref","first-page":"E98","DOI":"10.1093\/neuros\/nyy295","article-title":"Extracellular vesicles containing PD-L1 contribute to immune evasion in glioblastoma","volume":"83","author":"Lubin","year":"2018","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1515","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27031585","article-title":"Prostate cancer-associated fibroblasts: A review on CAF functions, heterogeneity, resistance mechanisms, and future in a chip","volume":"27","author":"Lupsa","year":"2026","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1520","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: Status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1525","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107532","article-title":"Super-enhancer redistribution as a mechanism of broad gene dysregulation in repeatedly drug-treated cancer cells","volume":"31","author":"Ma","year":"2020","journal-title":"Cell Reports"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109126_bb1530","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/neuonc\/noac107","article-title":"Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma","volume":"24","author":"Ma","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1535","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2023.113643","article-title":"Experimental models for preclinical cancer research","volume":"429","author":"Ma","year":"2023","journal-title":"Experimental Cell Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1540","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41420-022-01212-0","article-title":"GPX4-independent ferroptosis\u2014A new strategy in disease\u2019s therapy","volume":"8","author":"Ma","year":"2022","journal-title":"Cell Death Discovery"},{"issue":"40","key":"10.1016\/j.pharmthera.2026.109126_bb1545","doi-asserted-by":"crossref","first-page":"16282","DOI":"10.1073\/pnas.1202989109","article-title":"Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells","volume":"109","author":"Ma","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109126_bb1550","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1073\/pnas.1400272111","article-title":"Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance","volume":"111","author":"Ma","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109126_bb1555","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41419-020-2702-y","article-title":"Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition","volume":"11","author":"Makino","year":"2020","journal-title":"Cell Death & Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11658-021-00301-9","article-title":"The role of polyphenols in overcoming cancer drug resistance: A comprehensive review","volume":"27","author":"Maleki Dana","year":"2022","journal-title":"Cellular & Molecular Biology Letters"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109126_bb1565","first-page":"3458","article-title":"Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues","volume":"61","author":"Maliepaard","year":"2001","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb1570","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.tibtech.2015.01.004","article-title":"Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer","volume":"33","author":"Malik","year":"2015","journal-title":"Trends in Biotechnology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1575","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cell.2016.02.025","article-title":"Metastatic latency and immune evasion through autocrine inhibition of WNT","volume":"165","author":"Malladi","year":"2016","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb1580","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41573-024-00978-5","article-title":"Chromatin remodellers as therapeutic targets","volume":"23","author":"Malone","year":"2024","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb1585","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1590","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: A brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Advanced Pharmaceutical Bulletin"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1595","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport\u2014An update","volume":"17","author":"Mao","year":"2015","journal-title":"AAPS Journal"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109126_bb1600","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nature Reviews. Cancer"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb1605","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","article-title":"Platinum resistance: The role of DNA repair pathways","volume":"14","author":"Martin","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1610","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/B978-0-12-800249-0.00005-6","article-title":"ATP-dependent chromatin remodeling complexes as novel targets for cancer therapy","volume":"121","author":"Mayes","year":"2014","journal-title":"Advances in Cancer Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb1615","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrc2222","article-title":"Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis","volume":"7","author":"Menendez","year":"2007","journal-title":"Nature Reviews. Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1620","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/s41598-025-31128-5","article-title":"Targeting fibroblast activation protein in solid tumors via LNP-mediated CAR-mRNA delivery promotes durable regression in murine models","volume":"16","author":"Meng","year":"2025","journal-title":"Scientific Reports"},{"issue":"34","key":"10.1016\/j.pharmthera.2026.109126_bb1625","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/onc.2014.432","article-title":"A stress-induced early innate response causes multidrug tolerance in melanoma","volume":"34","author":"Menon","year":"2015","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb1630","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nature Reviews Drug Discovery"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb1635","article-title":"Current landscape of cancer immunotherapy: Harnessing the immune arsenal to overcome immune evasion","volume":"13","author":"Mitra","year":"2024","journal-title":"Biology-Basel"},{"issue":"Pt 16","key":"10.1016\/j.pharmthera.2026.109126_bb1640","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1242\/jcs.02554","article-title":"Non-Smad TGF-beta signals","volume":"118","author":"Moustakas","year":"2005","journal-title":"Journal of Cell Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1645","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010134","article-title":"The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy","volume":"13","author":"Mpakali","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109126_bb1650","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26209859","article-title":"Targeting the BCL2 family: Advances and challenges in BH3 mimetic-based therapies","volume":"26","author":"Mukherjee","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1655","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: New functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb1660","doi-asserted-by":"crossref","first-page":"253","DOI":"10.20892\/j.issn.2095-3941.2019.0284","article-title":"ABC transporters and the hallmarks of cancer: Roles in cancer aggressiveness beyond multidrug resistance","volume":"17","author":"Muriithi","year":"2020","journal-title":"Cancer Biology & Medicine"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1665","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.3816\/CBC.2010.s.015","article-title":"Evolving strategies for overcoming resistance to HER2-directed therapy: Targeting the PI3K\/Akt\/mTOR pathway","volume":"10","author":"Nahta","year":"2010","journal-title":"Clinical Breast Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb1670","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5732\/cjc.011.10320","article-title":"Breast cancer resistance protein (BCRP\/ABCG2): Its role in multidrug resistance and regulation of its gene expression","volume":"31","author":"Nakanishi","year":"2012","journal-title":"Chinese Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1675","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fcell.2019.00086","article-title":"The role of the extracellular matrix in cancer Stemness","volume":"7","author":"Nallanthighal","year":"2019","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"7326","key":"10.1016\/j.pharmthera.2026.109126_bb1680","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109126_bb1685","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discovery"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb1690","doi-asserted-by":"crossref","DOI":"10.1080\/23723556.2015.1098791","article-title":"Bidirectional interconversion of stem and non-stem cancer cell populations: A reassessment of theoretical models for tumor heterogeneity","volume":"3","author":"van Neerven","year":"2016","journal-title":"Molecular & Cellular Oncology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1695","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2026.101351","article-title":"Linc01833 drives gemcitabine resistance in non-small cell lung cancer by shielding SLC7A11 from WWP1-mediated ubiquitination and inhibiting ferroptosis","volume":"85","author":"Ni","year":"2026","journal-title":"Drug Resistance Updates"},{"issue":"294","key":"10.1016\/j.pharmthera.2026.109126_bb1700","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004652","article-title":"Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer","volume":"6","author":"Niederst","year":"2013","journal-title":"Science Signaling"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1705","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/13880209.2021.2017468","article-title":"Deciphering the molecular mechanism of tetrandrine in inhibiting hepatocellular carcinoma and increasing sorafenib sensitivity by combining network pharmacology and experimental evaluation","volume":"60","author":"Niu","year":"2022","journal-title":"Pharmaceutical Biology"},{"issue":"46","key":"10.1016\/j.pharmthera.2026.109126_bb1710","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.3748\/wjg.v28.i46.6433","article-title":"Recent progress in molecular mechanisms of postoperative recurrence and metastasis of hepatocellular carcinoma","volume":"28","author":"Niu","year":"2022","journal-title":"World Journal of Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1715","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1038\/s41467-024-50850-8","article-title":"DNA methylation and gene expression as determinants of genome-wide cell-free DNA fragmentation","volume":"15","author":"No\u00eb","year":"2024","journal-title":"Nature Communications"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb1720","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP inhibitor resistance: A tug-of-war in BRCA-mutated cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends in Cell Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb1725","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: Lessons for precision oncology","volume":"29","author":"O\u2019Dwyer","year":"2023","journal-title":"Nature Medicine"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109126_bb1730","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143371","article-title":"Emerging role of deubiquitinating enzymes (DUBs) in melanoma pathogenesis","volume":"14","author":"Ohanna","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb1735","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1740","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fimmu.2012.00190","article-title":"The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway","volume":"3","author":"Ohta","year":"2012","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb1745","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109126_bb1750","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1158\/0008-5472.CAN-25-0999","article-title":"Epigenetic heritability of cell plasticity drives cancer drug resistance through a one-to-many genotype-to-phenotype paradigm","volume":"85","author":"Oliveira","year":"2025","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1755","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: Origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb1760","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001107","article-title":"Mutant p53 gain-of-function in cancer","volume":"2","author":"Oren","year":"2010","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb1765","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041070","article-title":"Mitochondrial metabolism in pancreatic ductal adenocarcinoma: From mechanism-based perspectives to therapy","volume":"15","author":"Padinharayil","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1770","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discovery"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb1775","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/15476286.2019.1565665","article-title":"Foxo3a-dependent miR-633 regulates chemotherapeutic sensitivity in gastric cancer by targeting Fas-associated death domain","volume":"16","author":"Pang","year":"2019","journal-title":"RNA Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1780","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1785","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109126_bb1790","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bcp.2013.01.018","article-title":"Fibroblast-mediated drug resistance in cancer","volume":"85","author":"Paraiso","year":"2013","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1795","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6261721","article-title":"Cancer-associated immune resistance and evasion of immune surveillance in colorectal cancer","volume":"2016","author":"Parcesepe","year":"2016","journal-title":"Gastroenterology Research and Practice"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1800","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: Implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nature Reviews. Cancer"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109126_bb1805","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112317","article-title":"The Long noncoding RNA HOTAIR in breast cancer: Does autophagy play a role?","volume":"18","author":"Paw\u0142owska","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb1810","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189163","article-title":"Leveraging preclinical models of metastatic breast cancer","volume":"1879","author":"Pedroza","year":"2024","journal-title":"Biochimica Et Biophysica Acta. Reviews on Cancer"},{"issue":"13\u201314","key":"10.1016\/j.pharmthera.2026.109126_bb1815","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.addr.2013.09.004","article-title":"Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles","volume":"65","author":"Peetla","year":"2013","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb1820","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2131","article-title":"Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?","volume":"7","author":"Peinado","year":"2007","journal-title":"Nature Reviews. Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1825","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41420-025-02418-8","article-title":"Perspectives on cancer therapy\u2014Synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges","volume":"11","author":"Peng","year":"2025","journal-title":"Cell Death Discovery"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb1830","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.leukres.2007.09.015","article-title":"Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine","volume":"32","author":"Peng","year":"2008","journal-title":"Leukemia Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1835","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ame2.12032","article-title":"Enhancer and super-enhancer: Positive regulators in gene transcription","volume":"1","author":"Peng","year":"2018","journal-title":"Animal Models and Experimental Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1840","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tcb.2012.08.011","article-title":"Delving deeper: MCL-1's contributions to normal and cancer biology","volume":"23","author":"Perciavalle","year":"2013","journal-title":"Trends in Cell Biology"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109126_bb1845","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132490","article-title":"Transcriptomic analysis reveals early alterations associated with intrinsic resistance to targeted therapy in lung adenocarcinoma cell lines","volume":"16","author":"Perez-Medina","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb1850","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","article-title":"ROS in cancer therapy: The bright side of the moon","volume":"52","author":"Perillo","year":"2020","journal-title":"Experimental & Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1855","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6649314","article-title":"Similarities between tumour immune response and chronic wound microenvironment: Influence of mesenchymal stromal\/stem cells","volume":"2021","author":"Peta","year":"2021","journal-title":"Journal of Immunology Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1860","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1865","first-page":"1","article-title":"Cancer metabolic reprogramming: Importance, main features, and potentials for precise targeted anti-cancer therapies","volume":"11","author":"Phan","year":"2014","journal-title":"Cancer Biology & Medicine"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1870","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5416923","article-title":"Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cells International"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1875","article-title":"Immune resistance mechanisms and the road to personalized immunotherapy","volume":"43","author":"Piper","year":"2023","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1880","first-page":"673","article-title":"Cancer immunotherapy by targeting IDO1\/TDO and their downstream effectors","volume":"5","author":"Platten","year":"2014","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb1885","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nature Reviews Drug Discovery"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb1890","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109126_bb1895","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41568-024-00706-6","article-title":"Cancer organoids 2.0: Modelling the complexity of the tumour immune microenvironment","volume":"24","author":"Polak","year":"2024","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1900","first-page":"30528","article-title":"GPT2 mediates glutamine metabolism-driven metabolic alterations in platinum-resistant ovarian cancer cells","volume":"15","author":"Ponton-Almodovar","year":"2025","journal-title":"Research Square"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109126_bb1905","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","article-title":"The interplay between extracellular matrix remodeling and cancer therapeutics","volume":"14","author":"Prakash","year":"2024","journal-title":"Cancer Discovery"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1910","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"issue":"32","key":"10.1016\/j.pharmthera.2026.109126_bb1915","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1038\/s41388-018-0275-3","article-title":"Pro-tumorigenic roles of fibroblast activation protein in cancer: Back to the basics","volume":"37","author":"Pur\u00e9","year":"2018","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb1920","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/cncr.21227","article-title":"Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma","volume":"104","author":"Pusztai","year":"2005","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109126_bb1925","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1097\/CM9.0000000000001124","article-title":"Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer","volume":"133","author":"Qian","year":"2020","journal-title":"Chinese Medical Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb1930","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030612","article-title":"MET amplification as a resistance driver to TKI therapies in lung Cancer: Clinical challenges and opportunities","volume":"15","author":"Qin","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb1935","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41420-025-02670-y","article-title":"Mitochondrial metabolic reprogramming in colorectal cancer: Mechanisms of resistance and future clinical interventions","volume":"11","author":"Qiu","year":"2025","journal-title":"Cell Death Discovery"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109126_bb1940","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3003284","article-title":"Bi-directional metabolic reprogramming between cancer cells and T cells reshapes the anti-tumor immune response","volume":"23","author":"Qiu","year":"2025","journal-title":"PLoS Biology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1945","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1621812","article-title":"The tumor immune microenvironment: Implications for cancer immunotherapy, treatment strategies, and monitoring approaches","volume":"16","author":"Racacho","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"35","key":"10.1016\/j.pharmthera.2026.109126_bb1950","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41388-018-0297-x","article-title":"Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer","volume":"37","author":"Rada","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1955","doi-asserted-by":"crossref","DOI":"10.2147\/OTT.S581821","article-title":"Enhancing immunotherapy in diffuse large B-cell lymphoma: The synergistic potential of metabolic checkpoint inhibitors and immunomodulation","volume":"19","author":"Rajendraprasad","year":"2026","journal-title":"Oncotargets and Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb1960","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12020599","article-title":"A systems biology approach for addressing cisplatin resistance in non-small cell lung cancer","volume":"12","author":"Ramisetty","year":"2023","journal-title":"Journal of Clinical Medicine"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109126_bb1965","first-page":"5232","article-title":"Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins","volume":"57","author":"Rappa","year":"1997","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109126_bb1970","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2021.145796","article-title":"Up-down regulation of HIF-1\u03b1 in cancer progression","volume":"798","author":"Rashid","year":"2021","journal-title":"Gene"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109126_bb1975","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nature Medicine"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109126_bb1980","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1158\/1078-0432.CCR-05-1083","article-title":"ERCC1 and clinical resistance to platinum-based therapy","volume":"11","author":"Reed","year":"2005","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb1985","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1124\/mol.63.5.1094","article-title":"Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5","volume":"63","author":"Reid","year":"2003","journal-title":"Molecular Pharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb1990","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive immune resistance: How cancer protects from immune attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discovery"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb1995","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.canlet.2009.01.002","article-title":"Development of vorinostat: Current applications and future perspectives for cancer therapy","volume":"280","author":"Richon","year":"2009","journal-title":"Cancer Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2000","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb2005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109126_bb2010","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nature Reviews. Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4049\/jimmunol.0903399","article-title":"Proteases in MHC class I presentation and cross-presentation","volume":"184","author":"Rock","year":"2010","journal-title":"Journal of Immunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb2020","doi-asserted-by":"crossref","DOI":"10.3390\/genes15040501","article-title":"Principles in the Management of Glioblastoma","volume":"15","author":"Roda","year":"2024","journal-title":"Genes (Basel)"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb2025","article-title":"Effects of Ferroptosis on the metabolome in cardiac cells: The role of Glutaminolysis","volume":"11","author":"Rodr\u00edguez-Graciani","year":"2022","journal-title":"Antioxidants (Basel)"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb2030","first-page":"980","article-title":"Drug resistance in cancer immunotherapy: New strategies to improve checkpoint inhibitor therapies","volume":"2","author":"Rodriguez-Pascual","year":"2019","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1540610","article-title":"Zebrafish xenografts in breast cancer research","volume":"16","author":"Rong","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb2040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101041","article-title":"The SARS-CoV-2 Nsp3 macrodomain reverses PARP9\/DTX3L-dependent ADP-ribosylation induced by interferon signaling","volume":"297","author":"Russo","year":"2021","journal-title":"The Journal of Biological Chemistry"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb2045","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: From biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2050","series-title":"Drug Resistance in Bacteria, Fungi, Malaria, and Cancer","first-page":"47","article-title":"Molecular mechanism of drug resistance","volume":"22","author":"S","year":"2017"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb2055","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): Final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"The Lancet Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb2060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molmed.2018.12.009","article-title":"Principles of resistance to targeted cancer therapy: Lessons from basic and translational cancer biology","volume":"25","author":"Sabnis","year":"2019","journal-title":"Trends in Molecular Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2065","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2070","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.66109","article-title":"An epigenetic switch regulates the ontogeny of AXL-positive\/EGFR-TKi-resistant cells by modulating miR-335 expression","volume":"10","author":"Safaric Tepes","year":"2021","journal-title":"eLife"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb2075","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyag091","article-title":"Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma","volume":"31","author":"Safyan","year":"2026","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb2080","first-page":"604","article-title":"Minimal residual disease-directed adjuvant therapy for patients with early-stage colon cancer: CIRCULATE-US","volume":"36","author":"Sahin","year":"2022","journal-title":"Oncology (Williston Park, N.Y.)"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109126_bb2085","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1073\/pnas.0802047105","article-title":"Notch signaling mediates hypoxia-induced tumor cell migration and invasion","volume":"105","author":"Sahlgren","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7182","key":"10.1016\/j.pharmthera.2026.109126_bb2090","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109126_bb2095","doi-asserted-by":"crossref","DOI":"10.1097\/MS9.0000000000004155","article-title":"AI-enhanced liquid biopsy analysis for real-time monitoring of circulating tumor DNA mutations during targeted therapy resistance development","volume":"87","author":"Saleem","year":"2025","journal-title":"Annals of Medicine and Surgery"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1170264","article-title":"The role of tumor microenvironment in drug resistance: Emerging technologies to unravel breast cancer heterogeneity","volume":"13","author":"Salemme","year":"2023","journal-title":"Frontiers in Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb2105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.trecan.2018.01.001","article-title":"The genetic\/non-genetic duality of drug \u201cresistance\u201d in cancer","volume":"4","author":"Salgia","year":"2018","journal-title":"Trends Cancer"},{"issue":"43","key":"10.1016\/j.pharmthera.2026.109126_bb2110","first-page":"e9066","article-title":"Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer","volume":"114","author":"Sansone","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb2115","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432650","article-title":"TP53 mutations in acute Leukemias and myelodysplastic syndromes: Insights and treatment updates","volume":"44","author":"Santini","year":"2024","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb2120","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1152\/physrev.00037.2005","article-title":"Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system","volume":"86","author":"Sarkadi","year":"2006","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1701031","article-title":"Sleepyhead, deadly awakening: The dynamics of metastatic organotropism, tumor dormancy and therapeutic implications","volume":"15","author":"Sarkar","year":"2025","journal-title":"Frontiers in Oncology"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109126_bb2130","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the ABL kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb2135","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.trecan.2017.03.006","article-title":"Super-enhancer-driven transcriptional dependencies in cancer","volume":"3","author":"Sengupta","year":"2017","journal-title":"Trends Cancer"},{"issue":"75","key":"10.1016\/j.pharmthera.2026.109126_bb2140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Science Translational Medicine"},{"issue":"7403","key":"10.1016\/j.pharmthera.2026.109126_bb2145","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10933","article-title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","volume":"486","author":"Shah","year":"2012","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109126_bb2150","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1158\/0008-5472.CAN-19-0215","article-title":"Chemotherapy-induced distal enhancers drive transcriptional programs to maintain the Chemoresistant state in ovarian cancer","volume":"79","author":"Shang","year":"2019","journal-title":"Cancer Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb2155","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1002\/jcp.31093","article-title":"CircHIPK3 contributes to cisplatin resistance in gastric cancer by blocking autophagy-dependent ferroptosis","volume":"238","author":"Shang","year":"2023","journal-title":"Journal of Cellular Physiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb2160","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb2165","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/em.21736","article-title":"REV1 and DNA polymerase zeta in DNA interstrand crosslink repair","volume":"53","author":"Sharma","year":"2012","journal-title":"Environmental and Molecular Mutagenesis"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2170","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109126_bb2175","first-page":"4331","article-title":"Expulsion of small molecules in vesicles shed by cancer cells: Association with gene expression and chemosensitivity profiles","volume":"63","author":"Shedden","year":"2003","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2180","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discovery"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2185","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12672-025-01825-8","article-title":"Cancer-associated fibroblast-derived COL17A1 promotes gemcitabine resistance and tumorigenesis in pancreatic cancer cells by interacting with ACTN4","volume":"16","author":"Shi","year":"2025","journal-title":"Discover Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb2190","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: The mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb2195","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discovery"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2200","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109126_bb2205","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174236","article-title":"Genetics of ABCB1 in Cancer","volume":"15","author":"Skinner","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116277","article-title":"Risk factors of using late-autophagy inhibitors: Aspects to consider when combined with anticancer therapies","volume":"225","author":"Skrzeszewski","year":"2024","journal-title":"Biochemical Pharmacology"},{"issue":"44","key":"10.1016\/j.pharmthera.2026.109126_bb2215","doi-asserted-by":"crossref","first-page":"21963","DOI":"10.1073\/pnas.1915690116","article-title":"Linking long noncoding RNA to drug resistance","volume":"116","author":"Smallegan","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8101","key":"10.1016\/j.pharmthera.2026.109126_bb2220","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41586-025-09876-1","article-title":"Temporal tissue dynamics from a spatial snapshot","volume":"650","author":"Somer","year":"2026","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb2225","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.18632\/oncotarget.13907","article-title":"The role of tumor microenvironment in therapeutic resistance","volume":"8","author":"Son","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb2230","doi-asserted-by":"crossref","first-page":"8260","DOI":"10.3390\/ijms24098260","article-title":"Signal pathways in cancer","volume":"24","author":"Song","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb2235","article-title":"Targeting drug-tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells","volume":"4","author":"Song","year":"2023","journal-title":"MedComm (2020)"},{"issue":"Suppl","key":"10.1016\/j.pharmthera.2026.109126_bb2240","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.clml.2015.02.035","article-title":"Mutations in the BCR-ABL1 kinase domain and elsewhere in chronic myeloid leukemia","volume":"15","author":"Soverini","year":"2015","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2245","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13046-021-01908-8","article-title":"Fibronectin as a multiregulatory molecule crucial in tumor matrisome: From structural and functional features to clinical practice in oncology","volume":"40","author":"Spada","year":"2021","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109126_bb2250","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/1078-0432.CCR-04-0224","article-title":"The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma","volume":"10","author":"Spratlin","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb2255","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/mol.113.088609","article-title":"Molecular pharmacology of ABCG2 and its role in chemoresistance","volume":"84","author":"Stacy","year":"2013","journal-title":"Molecular Pharmacology"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109126_bb2260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814026","article-title":"Decoding the IL-33\/ST2 Axis: Its impact on the immune landscape of breast cancer","volume":"24","author":"Stojanovic","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb2265","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"38","key":"10.1016\/j.pharmthera.2026.109126_bb2270","doi-asserted-by":"crossref","first-page":"15101","DOI":"10.1073\/pnas.1213353109","article-title":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","volume":"109","author":"Stylianopoulos","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2275","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1016\/j.csbj.2025.09.011","article-title":"The role of super-enhancer-driven lncRNAs in cancer","volume":"27","author":"Su","year":"2025","journal-title":"Computational and Structural Biotechnology Journal"},{"issue":"7494","key":"10.1016\/j.pharmthera.2026.109126_bb2280","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2285","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101310","article-title":"Beyond the boundary: The emerging roles of ATP-binding cassette transporters in multidrug resistance (MDR) and therapeutic targeting in cancer","volume":"84","author":"Sun","year":"2026","journal-title":"Drug Resistance Updates"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2290","doi-asserted-by":"crossref","DOI":"10.1177\/15330338231161141","article-title":"NRF1 regulates the epithelial mesenchymal transition of breast cancer by modulating ROS homeostasis","volume":"22","author":"Sun","year":"2023","journal-title":"Technology in Cancer Research & Treatment"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109126_bb2295","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1002\/1873-3468.13967","article-title":"An inventory of lysosomal ABC transporters","volume":"594","author":"Szakacs","year":"2020","journal-title":"FEBS Letters"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb2300","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb2305","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.molcel.2020.10.010","article-title":"3D culture models with CRISPR screens reveal hyperactive NRF2 as a prerequisite for spheroid formation via regulation of proliferation and Ferroptosis","volume":"80","author":"Takahashi","year":"2020","journal-title":"Molecular Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2310","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/mol.106.023556","article-title":"Functional validation of the genetic polymorphisms of human ABC transporter ABCG2: Identification of alleles that are defective in porphyrin transport","volume":"70","author":"Tamura","year":"2006","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118106","article-title":"Recent update on the development of EZH2 inhibitors and degraders for cancer therapy","volume":"299","author":"Tang","year":"2025","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2320","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2325","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1612376","article-title":"Integrating artificial intelligence with circulating tumor DNA for non-small cell lung cancer: Opportunities, challenges, and future directions","volume":"12","author":"Thalambedu","year":"2025","journal-title":"Frontiers in Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109126_bb2330","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: Implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109126_bb2335","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","article-title":"Patient-derived tumor organoids: A new avenue for preclinical research and precision medicine in oncology","volume":"56","author":"Thorel","year":"2024","journal-title":"Experimental & Molecular Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb2340","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nature Medicine"},{"issue":"6282","key":"10.1016\/j.pharmthera.2026.109126_bb2345","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109126_bb2350","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1128\/MCB.00331-08","article-title":"Regulation of ABCG2 expression at the 3\u2032 untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line","volume":"28","author":"To","year":"2008","journal-title":"Molecular and Cellular Biology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb2355","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1158\/1535-7163.MCT-09-0292","article-title":"Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2","volume":"8","author":"To","year":"2009","journal-title":"Molecular Cancer Therapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb2360","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-13-1854","article-title":"Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes\/YAP axis","volume":"20","author":"Touil","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109126_bb2365","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nature Genetics"},{"issue":"5867","key":"10.1016\/j.pharmthera.2026.109126_bb2370","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1126\/science.1153124","article-title":"Ceramide triggers budding of exosome vesicles into multivesicular endosomes","volume":"319","author":"Trajkovic","year":"2008","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb2375","first-page":"1967","article-title":"Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil","volume":"41","author":"Tsuruo","year":"1981","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2380","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: Mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb2385","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cdd.2014.134","article-title":"New insights into IL-12-mediated tumor suppression","volume":"22","author":"Tugues","year":"2015","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2390","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3249766","article-title":"Matrix metalloproteinases in chemoresistance: Regulatory roles, molecular interactions, and potential inhibitors","volume":"2022","author":"Tune","year":"2022","journal-title":"Journal of Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109126_bb2395","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S1470-2045(26)00287-1","article-title":"Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): Extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"27","author":"Turner","year":"2026","journal-title":"The Lancet Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb2400","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41568-022-00479-w","article-title":"Functional lineage tracing to study the clonal evolution of therapy resistance","volume":"22","author":"Umkehrer","year":"2022","journal-title":"Nature Reviews Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb2405","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040813","article-title":"Ensartinib (X-396) effectively modulates pharmacokinetic resistance mediated by ABCB1 and ABCG2 drug efflux transporters and CYP3A4 biotransformation enzyme","volume":"12","author":"Vagiannis","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"42","key":"10.1016\/j.pharmthera.2026.109126_bb2410","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1038\/s41388-025-03582-y","article-title":"Adaptive cancer therapy: Can non-genetic factors become its achilles heel?","volume":"44","author":"Valcz","year":"2025","journal-title":"Oncogene"},{"issue":"27","key":"10.1016\/j.pharmthera.2026.109126_bb2415","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of Pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with Hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"7782","key":"10.1016\/j.pharmthera.2026.109126_bb2420","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"issue":"5659","key":"10.1016\/j.pharmthera.2026.109126_bb2425","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"issue":"7524","key":"10.1016\/j.pharmthera.2026.109126_bb2430","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nature13611","article-title":"Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function","volume":"514","author":"Viale","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2435","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41418-019-0362-1","article-title":"ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells","volume":"27","author":"Vidovic","year":"2020","journal-title":"Cell Death and Differentiation"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb2440","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the light: The growing complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb2445","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: Towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2450","article-title":"The role of m(6)A modification during macrophage metabolic reprogramming in human diseases and animal models","volume":"16","author":"Wang","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb2455","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.it.2024.01.009","article-title":"Targeting MHC-I inhibitory pathways for cancer immunotherapy","volume":"45","author":"Wang","year":"2024","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2460","article-title":"The mechanism of action and therapeutic potential of tumor-associated macrophages in tumor immune evasion","volume":"16","author":"Wang","year":"2025","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2465","article-title":"Current progress and future perspective of super-enhancers: A viable and effective bridge between the transcriptional apparatus and disease","volume":"16","author":"Wang","year":"2025","journal-title":"Frontiers in Genetics"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb2470","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/cas.13150","article-title":"Increasing circulating exosomes-carrying TRPC5 predicts chemoresistance in metastatic breast cancer patients","volume":"108","author":"Wang","year":"2017","journal-title":"Cancer Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb2475","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s12276-026-01673-8","article-title":"PARP inhibitors and breast cancer: From therapeutic breakthrough to resistance challenge","volume":"58","author":"Wang","year":"2026","journal-title":"Experimental & Molecular Medicine"},{"issue":"8061","key":"10.1016\/j.pharmthera.2026.109126_bb2480","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41586-025-08758-w","article-title":"STING agonist-based ER-targeting molecules boost antigen cross-presentation","volume":"641","author":"Wang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2485","article-title":"Identification and validation of angiogenesis-related gene expression for predicting prognosis in patients with ovarian cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2490","first-page":"47","article-title":"Mechanism of ferroptosis resistance in cancer cells","volume":"7","author":"Wang","year":"2024","journal-title":"Cancer Drug Resistance"},{"issue":"30","key":"10.1016\/j.pharmthera.2026.109126_bb2495","doi-asserted-by":"crossref","first-page":"47444","DOI":"10.18632\/oncotarget.10165","article-title":"MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K\/AKT pathway activity","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109126_bb2500","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/s41418-022-01008-w","article-title":"Wnt\/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer","volume":"29","author":"Wang","year":"2022","journal-title":"Cell Death and Differentiation"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2505","doi-asserted-by":"crossref","first-page":"10048","DOI":"10.1038\/s41467-025-66376-6","article-title":"Drug-tolerant persister cells in cancer: Bridging the gaps between bench and bedside","volume":"16","author":"Wang","year":"2025","journal-title":"Nature Communications"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109126_bb2510","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1038\/s41388-021-01781-x","article-title":"Exploiting vulnerabilities of SWI\/SNF chromatin remodelling complexes for cancer therapy","volume":"40","author":"Wanior","year":"2021","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109126_bb2515","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nature Reviews Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb2520","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2525","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2017.00292","article-title":"Major histocompatibility complex (MHC) class I and MHC class II proteins: Conformational plasticity in antigen presentation","volume":"8","author":"Wieczorek","year":"2017","journal-title":"Frontiers in Immunology"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2026.109126_bb2530","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.drup.2012.01.008","article-title":"Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance","volume":"15","author":"Wilting","year":"2012","journal-title":"Drug Resistance Updates"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109126_bb2535","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109126_bb2540","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012704","article-title":"Molecular mechanisms of RSV and air pollution interaction: A scoping review","volume":"23","author":"Wrotek","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109126_bb2545","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e39984","article-title":"Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastoma","volume":"10","author":"Wu","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2550","doi-asserted-by":"crossref","DOI":"10.1186\/s42523-026-00527-y","article-title":"Host genome regulation of the porcine gut microbiota and its impact on feed conversion efficiency","volume":"8","author":"Wu","year":"2026","journal-title":"Animal Microbiome"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2555","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fonc.2019.00407","article-title":"The role of lncRNAs in the distant metastasis of breast cancer","volume":"9","author":"Wu","year":"2019","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2560","article-title":"Nestin in multiple myeloma: Emerging insights into a potential therapeutic target","volume":"15","author":"Wu","year":"2025","journal-title":"Frontiers in Oncology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109126_bb2565","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/ijc.24249","article-title":"Induction of myeloid-derived suppressor cells by tumor exosomes","volume":"124","author":"Xiang","year":"2009","journal-title":"International Journal of Cancer"},{"issue":"48","key":"10.1016\/j.pharmthera.2026.109126_bb2570","doi-asserted-by":"crossref","first-page":"20792","DOI":"10.1073\/pnas.1011412107","article-title":"Error-prone translesion synthesis mediates acquired chemoresistance","volume":"107","author":"Xie","year":"2010","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109126_bb2575","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/cr.2009.5","article-title":"TGF-beta-induced epithelial to mesenchymal transition","volume":"19","author":"Xu","year":"2009","journal-title":"Cell Research"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2580","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101275","article-title":"Hypoxia-induced upregulation of HIF1A-AS3 promotes MSC transition to cancer-associated fibroblasts and confers drug resistance in gastric cancer","volume":"82","author":"Xu","year":"2025","journal-title":"Drug Resistance Updates"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2585","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10549-015-3304-8","article-title":"Targeting metabolic plasticity in breast cancer cells via mitochondrial complex I modulation","volume":"150","author":"Xu","year":"2015","journal-title":"Breast Cancer Research and Treatment"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109126_bb2590","doi-asserted-by":"crossref","DOI":"10.3390\/cells11193074","article-title":"The emerging roles and clinical potential of circSMARCA5 in cancer","volume":"11","author":"Xue","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb2595","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s13238-016-0330-1","article-title":"Evolution from genetics to phenotype: Reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance","volume":"8","author":"Xue","year":"2017","journal-title":"Protein & Cell"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2600","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3389\/fonc.2020.01010","article-title":"Metabolic adaptations in cancer stem cells","volume":"10","author":"Yadav","year":"2020","journal-title":"Frontiers in Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109126_bb2605","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.stem.2023.05.012","article-title":"Organoid cultures for cancer modeling","volume":"30","author":"Yan","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2610","doi-asserted-by":"crossref","first-page":"16345","DOI":"10.1007\/s13277-016-5448-5","article-title":"LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K\/AKT\/MRP1 genes","volume":"37","author":"Yan","year":"2016","journal-title":"Tumour Biology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2615","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.18632\/oncotarget.27995","article-title":"Interferon-\u03b3\/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC)","author":"Yan","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2620","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2147\/IJN.S445578","article-title":"Nanoplatform-mediated autophagy regulation and combined anti-tumor therapy for resistant tumors","volume":"19","author":"Yang","year":"2024","journal-title":"International Journal of Nanomedicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2625","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cllc.2025.10.018","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor-mutated, MET-amplified advanced non-small cell lung cancer: A randomized phase II trial","volume":"27","author":"Yang","year":"2026","journal-title":"Clinical Lung Cancer"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2630","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41423-026-01424-9","article-title":"Adaptive resistance in cancer immunotherapy","volume":"23","author":"Yang","year":"2026","journal-title":"Cellular & Molecular Immunology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2635","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3389\/fphar.2019.00709","article-title":"Emodin induced SREBP1-dependent and SREBP1-independent apoptosis in hepatocellular carcinoma cells","volume":"10","author":"Yang","year":"2019","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2640","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41392-026-02664-x","article-title":"Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistance","volume":"11","author":"Yang","year":"2026","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb2645","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ccell.2025.03.018","article-title":"New horizons at the interface of artificial intelligence and translational cancer research","volume":"43","author":"Yates","year":"2025","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb2650","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s10120-025-01657-z","article-title":"Targeting yes-associated protein to overcome imatinib resistance in gastrointestinal stromal tumor drug-tolerant persister cells","volume":"28","author":"Yokouchi","year":"2025","journal-title":"Gastric Cancer"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109126_bb2655","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/ncb1508","article-title":"A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells","volume":"8","author":"Yook","year":"2006","journal-title":"Nature Cell Biology"},{"issue":"28","key":"10.1016\/j.pharmthera.2026.109126_bb2660","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1016\/S0021-9258(17)44885-X","article-title":"Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A","volume":"265","author":"Yoshida","year":"1990","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2665","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: Opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb2670","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cllc.2021.06.006","article-title":"Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced\/metastatic non-small cell lung cancer whose disease has progressed on first-line Osimertinib therapy (ORCHARD)","volume":"22","author":"Yu","year":"2021","journal-title":"Clinical Lung Cancer"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2675","article-title":"Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma","volume":"13","author":"Yu","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2680","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.exphem.2021.08.010","article-title":"miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK\/Nf-\u03bab signaling pathway in mantle cell lymphoma","volume":"103","author":"Yuan","year":"2021","journal-title":"Experimental Hematology"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2685","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan","year":"2019","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2690","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41419-025-07807-6","article-title":"Targeting the TRIM14\/USP14 axis enhances radiotherapy efficacy by inducing GPX4 degradation and disrupting ferroptotic defense in HCC","volume":"16","author":"Yue","year":"2025","journal-title":"Cell Death & Disease"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109126_bb2695","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb2700","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"37","key":"10.1016\/j.pharmthera.2026.109126_bb2705","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1038\/sj.onc.1208927","article-title":"TGF-beta and epithelial-to-mesenchymal transitions","volume":"24","author":"Zavadil","year":"2005","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb2710","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12032-025-02626-3","article-title":"Exosomes and solid cancer therapy: Where are we now?","volume":"42","author":"Zemanek","year":"2025","journal-title":"Medical Oncology"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109126_bb2715","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1039\/D4NA00285G","article-title":"Smart delivery vehicles for cancer: Categories, unique roles and therapeutic strategies","volume":"6","author":"Zeng","year":"2024","journal-title":"Nanoscale Advances"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2720","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.celrep.2015.08.069","article-title":"LncRNA HOTAIR enhances the androgen-receptor-mediated transcriptional program and drives castration-resistant prostate cancer","volume":"13","author":"Zhang","year":"2015","journal-title":"Cell Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2725","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s40364-024-00646-1","article-title":"Metabolic reprogramming and immune evasion: The interplay in the tumor microenvironment","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomarker Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2730","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41467-017-01968-5","article-title":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","volume":"8","author":"Zhang","year":"2017","journal-title":"Nature Communications"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb2735","first-page":"8000","article-title":"A systematic pan-cancer analysis identifies LDHA as a novel predictor for immunological, prognostic, and immunotherapy resistance","volume":"16","author":"Zhang","year":"2024","journal-title":"Aging (Albany NY)"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109126_bb2740","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/1759-7714.13450","article-title":"LncRNA HOTAIR enhances breast cancer radioresistance through facilitating HSPA1A expression via sequestering miR-449b-5p","volume":"11","author":"Zhang","year":"2020","journal-title":"Thorac Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109126_bb2745","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/FJC.0000000000001211","article-title":"Changes in microRNA expression profiles in diabetic cardiomyopathy rats following H3 Relaxin treatment","volume":"79","author":"Zhang","year":"2022","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2750","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40659-020-00286-3","article-title":"Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1","volume":"53","author":"Zhang","year":"2020","journal-title":"Biological Research"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2755","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104483","article-title":"Redox signaling in drug-tolerant persister cells as an emerging therapeutic target","volume":"89","author":"Zhang","year":"2023","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109126_bb2760","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","article-title":"Stromal cells in the tumor microenvironment: Accomplices of tumor progression?","volume":"14","author":"Zhao","year":"2023","journal-title":"Cell Death & Disease"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109126_bb2765","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1093\/nar\/gkac778","article-title":"Super-enhancer-controlled positive feedback loop BRD4\/ER\u03b1-RET-ER\u03b1 promotes ER\u03b1-positive breast cancer","volume":"50","author":"Zheng","year":"2022","journal-title":"Nucleic Acids Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2770","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13048-021-00939-1","article-title":"MicroRNA-625-3p improved proliferation and involved chemotherapy resistance via targeting PTEN in high grade ovarian serous carcinoma","volume":"15","author":"Zhong","year":"2022","journal-title":"Journal of Ovarian Research"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2026.109126_bb2775","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/08830180902978120","article-title":"Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation","volume":"28","author":"Zhou","year":"2009","journal-title":"International Reviews of Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109126_bb2780","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13402-025-01138-6","article-title":"The cross-talk and interplay between ferroptosis and cuproptosis in tumor and therapeutics","volume":"49","author":"Zhou","year":"2026","journal-title":"Cellular Oncology (Dordrecht)"},{"key":"10.1016\/j.pharmthera.2026.109126_bb2785","article-title":"Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications","volume":"12","author":"Zhou","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109126_bb2790","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3892\/ol.2017.5587","article-title":"Long non-coding RNA HOTAIR enhances radioresistance in MDA-MB231 breast cancer cells","volume":"13","author":"Zhou","year":"2017","journal-title":"Oncology Letters"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109126_bb2795","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.bcp.2008.06.007","article-title":"Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1\/P-glycoprotein expression in human cancer cells","volume":"76","author":"Zhu","year":"2008","journal-title":"Biochemical Pharmacology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:00:53Z","timestamp":1794412853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826001531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":558,"alternative-id":["S0163725826001531"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109126","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug resistance in cancer: Emerging mechanisms, translational barriers, and pharmacological strategies","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109126"}}